Financing

Kesmalea becomes Oyster Therapeutics and raises $60 million for tau degraders

The London protein-degrader company, now called Oyster Therapeutics, has raised $60 million in a Series A-2 round led by 4BIO Capital. The money will push its lead tau degrader, an oral drug designed to reach the brain, toward the clinic and support the SELFTAC platform. Oyster is also funding tau biology research at Massachusetts General Hospital.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call